| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H25ClN4O2S |
| Molecular Weight | 456.988 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NN=C2[C@H](CC(=O)OC(C)(C)C)N=C(C3=C(SC(C)=C3C)N12)C4=CC=C(Cl)C=C4
InChI
InChIKey=DNVXATUJJDPFDM-KRWDZBQOSA-N
InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1
(+)-JQ1 is a selective and potent inhibitor of Bromodomain and Extra-Terminal motif (BET) proteins. These are important epigenetic regulators facilitating the transcription of genes in chromatin areas linked to acetylated histones. (+)-JQ1 engages the bromodomain pocket in a manner that is competitive with acetylated peptide binding, thereby causing the displacement of BET proteins from chromatin. However, the inhibitor’s half life is only one hour, so it has short-lasting effects.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 33.0 nM [IC50] | |||
| 49.0 nM [Kd] | |||
| 128.4 nM [Kd] | |||
| 59.5 nM [Kd] | |||
| 190.1 nM [Kd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
Patents
Sample Use Guides
JQ1 displaces BET domain containing proteins such as BRD4 from nuclear chromatin in vitro, induces squamous cell differentiation and growth arrest in NUT midline carcinoma (NMC) cells and exhibits antitumour activity in xenograft models of NMC. (+)-JQ1 binds to BRD4-BD1 with a Kd of approximately 50 nM and to BRD4-BD2 with a Kd of 90 nM.
ACTIVE MOIETY
